The L-type Ca2+ channel as a therapeutic target in heart disease

Current Medicinal Chemistry

Volumn 16, Issue 26, 2009, Pages 3341-3358

  Viola, H M ^a   Macdonald, W A ^a   Tang, H ^a   Hool, L C ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Calcium homeostasis; Cardiac hypertrophy; L type Ca2+ channel; L type Ca2+ channel antagonists; Reactive oxygen species

Indexed keywords

ACTIN; AMIODARONE; AMLODIPINE; BENZODIAZEPINE DERIVATIVE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CYCLOHEXIMIDE; CYCLOSPORIN; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; GROWTH PROMOTOR; HISTONE DEACETYLASE 5; INOSITOL TRISPHOSPHATE; METHYLPREDNISOLONE; MIBEFRADIL; MYOSIN; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; NIFEDIPINE; NISOLDIPINE; PHENYLALKYLAMINE; PLACEBO; REACTIVE OXYGEN METABOLITE; RUBOXISTAURIN; RYANODINE RECEPTOR; SIMVASTATIN; SODIUM CALCIUM EXCHANGE PROTEIN; TACROLIMUS; VERAPAMIL;

ANGINA PECTORIS; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; HEART DISEASE; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE EXCITABILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE POTENTIAL; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; REVIEW; SARCOPLASMIC RETICULUM; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; CALCIUM; CALCIUM CHANNEL AGONISTS; CALCIUM CHANNELS, L-TYPE; CARDIOMEGALY; DOGS; HEART DISEASES; HUMANS; MOLECULAR SEQUENCE DATA; RATS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 70450210244     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709789057671     Document Type: Review

References (237)

1. American Heart Association Heart and Stroke Statistical Update. Circulation, 2006, 113, 85-151.
2. Bers, D.M. Calcium cycling and signaling in cardiac myocytes. Annu. Rev. Physiol., 2008, 70, 23-49.
3. Carafoli, E.; Santella, L.; Branca, D.; Brini, M. Generation, control, and processing of cellular calcium signals. Crit. Rev. Biochem. Mol. Biol., 2001, 36, 107-260.
4. Bodi, I.; Mikala, G.; Koch, S.E.; Akhter, S.A.; Schwartz, A. The Ltype calcium channel in the heart: the beat goes on. J. Clin. Invest., 2005, 115, 3306-3317 (Pubitemid 43121813)
5. Hund, T.J.; Ziman, A.P.; Lederer, W.J.; Mohler, P.J. The cardiac IP3 receptor: uncovering the role of "the other" calcium-release channel. J. Mol. Cell Cardiol., 2008, 45, 159-161
6. Moschella, M.C.; Marks, A.R. Inositol 1,4,5-trisphosphate receptor expression in cardiac myocytes. J. Cell Biol., 1993, 120, 1137-1146 (Pubitemid 23064168)
7. Wu, X.; Zhang, T.; Bossuyt, J.; Li, X.; McKinsey, T.A.; Dedman, J.R.; Olson, E.N.; Chen, J.; Brown, J.H.; Bers, D.M. Local InsP3-dependent perinuclear Ca2+ signaling in cardiac myocyte excitation-transcription coupling. J. Clin. Invest., 2006, 116, 675-682
8. Domeier, T.L.; Zima, A.V.; Maxwell, J.T.; Huke, S.; Mignery, G.A.; Blatter, L.A. IP3 receptor-dependent Ca2+ release modulates excitation- contraction coupling in rabbit ventricular myocytes. Am. J. Physiol. Heart Circ. Physiol., 2008, 294, H596-604.
9. Hool, L.C. What cardiologists should know about calcium ion channels and their regulation by reactive oxygen species. Heart Lung Circ., 2007, 16, 361-372
10. Bezprozvanny, I.; Watras, J.; Ehrlich, B.E. Bell-shaped calcium-response curves of Ins(1,4,5)P3- and calcium-gated channels from endoplasmic reticulum of cerebellum. Nature, 1991, 351, 751-754
11. Viola, H.M.; Hool, L.C. The role of calcium and the L-type calcium channel in pathological remodeling of the heart. Vascular Disease Prevention, 2008, 5, 104-115
12. Hool, L.C.; Corry, B. Redox control of calcium channels: from mechanisms to therapeutic opportunities. Antioxid. Redox Signal., 2007, 9, 409-435 (Pubitemid 46311006)
13. Guinamard, R.; Demion, M.; Chatelier, A.; Bois, P. Calcium-activated nonselective cation channels in mammalian cardiomyocytes. Trends Cardiovasc. Med., 2006, 16, 245-250 (Pubitemid 44374369)
14. Bush, E.W.; Hood, D.B.; Papst, P.J.; Chapo, J.A.; Minobe, W.; Bristow, M.R.; Olson, E.N.; McKinsey, T.A. Canonical transient receptor potential channels promote cardiomyocyte hypertrophy through activation of calcineurin signaling. J. Biol. Chem., 2006, 281, 33487-33496
15. Satoh, S.; Tanaka, H.; Ueda, Y.; Oyama, J.; Sugano, M.; Sumimoto, H.; Mori, Y.; Makino, N. Transient receptor potential (TRP) protein 7 acts as a G protein-activated Ca2+ channel mediating angiotensin II-induced myocardial apoptosis. Mol. Cell Biochem., 2007, 294, 205-215 (Pubitemid 46188902)
16. Fonfria, E.; Murdock, P.R.; Cusdin, F.S.; Benham, C.D.; Kelsell, R.E.; McNulty, S. Tissue distribution profiles of the human TRPM cation channel family. J. Recept. Signal. Transduct. Res., 2006, 26, 159-178
17. Nakayama, H.; Wilkin, B.J.; Bodi, I.; Molkentin, J.D. Calcineurin-dependent cardiomyopathy is activated by TRPC in the adult mouse heart. FASEB J., 2006, 20, 1660-1670
18. Jaleel, N.; Nakayama, H.; Chen, X.; Kubo, H.; MacDonnell, S.; Zhang, H.; Berretta, R.; Robbins, J.; Cribbs, L.; Molkentin, J.D.; Houser, S.R. Ca2+ influx through T- and L-type Ca2+ channels have different effects on myocyte contractility and induce unique cardiac phenotypes. Circ. Res., 2008, 103, 1109-1119
19. Jurkat-Rott, K.; Lehmann-Horn, F. The impact of splice isoforms on voltage-gated calcium channel alpha1 subunits. J. Physiol., 2004, 554, 609-619 (Pubitemid 38219878)
20. Ertel, E.A.; Campbell, K.P.; Harpold, M.M.; Hofmann, F.; Mori, Y.; Perez-Reyes, E.; Schwartz, A.; Snutch, T.P.; Tanabe, T.; Birnbaumer, L.; Tsien, R.W.; Catterall, W.A. Nomenclature of voltage-gated calcium channels. Neuron, 2000, 25, 533-535
21. Hille, B.: Ion channels of excitable membranes; Sinauer: Sunderland, Mass., 2001.
22. Klockner, U.; Mikala, G.; Eisfeld, J.; Iles, D.E.; Strobeck, M.; Mershon, J.L.; Schwartz, A.; Varadi, G. Properties of three COOH-terminal splice variants of a human cardiac L-type Ca2+-channel alpha1-subunit. Am. J. Physiol., 1997, 272, H1372-81.
23. Pragnell, M.; De Waard, M.; Mori, Y.; Tanabe, T.; Snutch, T.P.; Campbell, K.P. Calcium channel beta-subunit binds to a conserved motif in the I-II cytoplasmic linker of the alpha 1-subunit. Nature, 1994, 368, 67-70.
24. Catterall, W.A. Structure and regulation of voltage-gated Ca2+ channels. Annu. Rev. Cell Dev. Biol., 2000, 16, 521-555
25. Cingolani, E.; Ramirez Correa, G.A.; Kizana, E.; Murata, M.; Cheol Cho, H.; Marban, E. Gene Therapy to Inhibit the Calcium Channel {beta} Subunit. Physiological Consequences and Pathophysiological Effects in Models of Cardiac Hypertrophy. Circ. Res., 2007,
26. Dolphin, A.C. Beta subunits of voltage-gated calcium channels. J. Bioenerg. Biomembr., 2003, 35, 599-620. (Pubitemid 38124815)
27. Hering, S. beta-Subunits: fine tuning of Ca(2+) channel block. Trends Pharmacol. Sci., 2002, 23, 509-513
28. Jay, S.D.; Sharp, A.H.; Kahl, S.D.; Vedvick, T.S.; Harpold, M.M.; Campbell, K.P. Structural characterization of the dihydropyridine-sensitive calcium channel alpha 2-subunit and the associated delta peptides. J. Biol. Chem., 1991, 266, 3287-3293
29. Klugbauer, N.; Lacinova, L.; Marais, E.; Hobom, M.; Hofmann, F. Molecular diversity of the calcium channel alpha2delta subunit. J. Neurosci., 1999, 19, 684-691
30. Hess, P.; Lansman, J.B.; Tsien, R.W. Different modes of Ca channel gating behaviour favoured by dihydropyridine Ca agonists and antagonists. Nature, 1984, 311, 538-544
31. Cavalie, A.; Pelzer, D.; Trautwein, W. Fast and slow gating behaviour of single calcium channels in cardiac cells. Relation to activation and inactivation of calcium-channel current. Pflugers Arch., 1986, 406, 241-258
32. Carmeliet, E. Cardiac ionic currents and acute ischemia: from channels to arrhythmias. Physiol. Rev., 1999, 79, 917-1017. (Pubitemid 29330175)
33. Yue, D.T.; Marban, E. Permeation in the dihydropyridine-sensitive calcium channel. Multi-ion occupancy but no anomalous mole-fraction effect between Ba2+ and Ca2+. J. Gen. Physiol., 1990, 95, 911-939 (Pubitemid 20171078)
34. McDonald, T.F.; Pelzer, S.; Trautwein, W.; Pelzer, D.J. Regulation and modulation of calcium channels in cardiac, skeletal, and smooth muscle cells. Physiol. Rev., 1994, 74, 365-507. (Pubitemid 24127646)
35. Kamp, T.J.; Hell, J.W. Regulation of cardiac L-type calcium channels by protein kinase A and protein kinase C. Circ. Res., 2000, 87, 1095-1102
36. van der Heyden, M.A.; Wijnhoven, T.J.; Opthof, T. Molecular aspects of adrenergic modulation of cardiac L-type Ca2+ channels. Cardiovasc. Res., 2005, 65, 28-39. (Pubitemid 40038476)
37. Gao, T.; Yatani, A.; Dell'Acqua, M.L.; Sako, H.; Green, S.A.; Dascal, N.; Scott, J.D.; Hosey, M.M. cAMP-dependent regulation of cardiac L-type Ca2+ channels requires membrane targeting of PKA and phosphorylation of channel subunits. Neuron, 1997, 19, 185-196
38. Yoshida, A.; Takahashi, M.; Nishimura, S.; Takeshima, H.; Kokubun, S. Cyclic AMP-dependent phosphorylation and regulation of the cardiac dihydropyridine-sensitive Ca channel. FEBS Lett., 1992, 309, 343-349
39. Ganesan, A.N.; Maack, C.; Johns, D.C.; Sidor, A.; O'Rourke, B. Beta-adrenergic stimulation of L-type Ca2+ channels in cardiac myocytes requires the distal carboxyl terminus of alpha1C but not serine 1928. Circ Res, 2006, 98, e11-8.
40. Shistik, E.; Keren-Raifman, T.; Idelson, G.H.; Blumenstein, Y.; Dascal, N.; Ivanina, T. The N terminus of the cardiac L-type Ca(2+) channel alpha(1C) subunit. The initial segment is ubiquitous and crucial for protein kinase C modulation, but is not directly phosphorylated. J. Biol. Chem., 1999, 274, 31145-31149 (Pubitemid 129501557)
41. Zuhlke, R.D.; Pitt, G.S.; Deisseroth, K.; Tsien, R.W.; Reuter, H. Calmodulin supports both inactivation and facilitation of L-type calcium channels. Nature, 1999, 399, 159-162 (Pubitemid 129524348)
42. Soldatov, N.M.; Zuhlke, R.D.; Bouron, A.; Reuter, H. Molecular structures involved in L-type calcium channel inactivation. Role of the carboxyl-terminal region encoded by exons 40-42 in alpha1C subunit in the kinetics and Ca2+ dependence of inactivation. J. Biol. Chem., 1997, 272, 3560-3566 (Pubitemid 27066860)
43. Yuan, W.; Bers, D.M. Ca-dependent facilitation of cardiac Ca current is due to Ca-calmodulin-dependent protein kinase. Am. J. Physiol., 1994, 267, H982-93.
44. Halliwell, B.; Whiteman, M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br. J. Pharmacol., 2004, 142, 231-255 (Pubitemid 38746160)
45. Halliwell, B. The role of oxygen radicals in human disease, with particular reference to the vascular system. Haemostasis, 1993, 23(Suppl 1), 118-126 (Pubitemid 23116285)
46. Thannickal, V.J.; Fanburg, B.L. Reactive oxygen species in cell signaling. Am. J. Physiol. Lung Cell Mol. Physiol., 2000, 279, L1005-28.
47. Sabri, A.; Hughie, H.H.; Lucchesi, P.A. Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes. Antioxid Redox Signal., 2003, 5, 731-740
48. Khan, A.U.; Wilson, T. Reactive oxygen species as cellular messengers. Chem. Biol., 1995, 2, 437-445
49. Campbell, D.L.; Stamler, J.S.; Strauss, H.C. Redox modulation of L-type calcium channels in ferret ventricular myocytes. Dual mechanism regulation by nitric oxide and S-nitrosothiols. J. Gen. Physiol., 1996, 108, 277-293
50. Lipton, S.A.; Choi, Y.B.; Pan, Z.H.; Lei, S.Z.; Chen, H.S.; Sucher, N.J.; Loscalzo, J.; Singel, D.J.; Stamler, J.S. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature, 1993, 364, 626-632 (Pubitemid 23274719)
51. Gilbert, H.F. Molecular and cellular aspects of thiol-disulfide exchange. Adv. Enzymol Relat Areas Mol. Biol., 1990, 63, 69-172.
52. Hool, L.C.; Di Maria, C.A.; Viola, H.M.; Arthur, P.G. Role of NAD(P)H oxidase in the regulation of cardiac L-type Ca2+ channel function during acute hypoxia. Cardiovasc. Res., 2005, 67, 624-635
53. Hool, L.C. Hypoxia increases the sensitivity of the L-type Ca(2+) current to beta-adrenergic receptor stimulation via a C2 region-containing protein kinase C isoform. Circ. Res., 2000, 87, 1164-1171
54. Hool, L.C.; Arthur, P.G. Decreasing cellular hydrogen peroxide with catalase mimics the effects of hypoxia on the sensitivity of the L-type Ca2+ channel to beta-adrenergic receptor stimulation in cardiac myocytes. Circ. Res., 2002, 91, 601-609
55. Hudasek, K.; Brown, S.T.; Fearon, I.M. H2O2 regulates recombinant Ca2+ channel alpha1C subunits but does not mediate their sensitivity to acute hypoxia. Biochem. Biophys. Res. Commun., 2004, 318, 135-141
56. Viola, H.M.; Arthur, P.G.; Hool, L.C. Transient exposure to hydrogen peroxide causes an increase in mitochondria-derived superoxide as a result of sustained alteration in L-type Ca2+ channel function in the absence of apoptosis in ventricular myocytes. Circ. Res., 2007, 100, 1036-1044
57. Hool, L.C. Hypoxia alters the sensitivity of the L-type Ca(2+) channel to alpha-adrenergic receptor stimulation in the presence of beta-adrenergic receptor stimulation. Circ. Res., 2001, 88, 1036-1043
58. Sims, C.; Harvey, R.D. Redox modulation of basal and beta-adrenergically stimulated cardiac L-type Ca(2+) channel activity by phenylarsine oxide. Br. J. Pharmacol., 2004, 142, 797-807.
59. Akaishi, T.; Nakazawa, K.; Sato, K.; Saito, H.; Ohno, Y.; Ito, Y. Hydrogen peroxide modulates whole cell Ca2+ currents through L-type channels in cultured rat dentate granule cells. Neurosci. Lett., 2004, 356, 25-28 (Pubitemid 38121498)
60. Fearon, I.M.; Palmer, A.C.; Balmforth, A.J.; Ball, S.G.; Varadi, G.; Peers, C. Modulation of recombinant human cardiac L-type Ca2+ channel alpha1C subunits by redox agents and hypoxia. J. Physiol., 1999, 514(Pt 3), 629-637 (Pubitemid 29060310)
61. Scragg, J.L.; Dallas, M.L.; Wilkinson, J.A.; Varadi, G.; Peers, C. Carbon monoxide inhibits L-type Ca2+ channels via redox modulation of key cysteine residues by mitochondrial reactive oxygen species. J. Biol. Chem., 2008, 283, 24412-24419
62. Berridge, M.J. Calcium microdomains: organization and function. Cell Calcium, 2006, 40, 405-412
63. Berridge, M.J. Remodelling Ca2+ signalling systems and cardiac hypertrophy. Biochem. Soc. Trans., 2006, 34, 228-231
64. Xin, H.B.; Senbonmatsu, T.; Cheng, D.S.; Wang, Y.X.; Copello, J.A.; Ji, G.J.; Collier, M.L.; Deng, K.Y.; Jeyakumar, L.H.; Magnuson, M.A.; Inagami, T.; Kotlikoff, M.I.; Fleischer, S. Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy. Nature, 2002, 416, 334-338
65. Kirchhefer, U.; Neumann, J.; Baba, H.A.; Begrow, F.; Kobayashi, Y.M.; Reinke, U.; Schmitz, W.; Jones, L.R. Cardiac hypertrophy and impaired relaxation in transgenic mice overexpressing triadin 1. J. Biol. Chem., 2001, 276, 4142-4149 (Pubitemid 37371499)
66. Cooper, G., 4th Cardiocyte adaptation to chronically altered load. Annu. Rev. Physiol., 1987, 49, 501-518
67. Mondry, A.; Swynghedauw, B. Biological adaptation of the myocardium to chronic mechanical overload. Molecular determinants of the autonomic nervous system. Eur. Heart J., 1995, 16(Suppl I), 64-73.
68. Frey, N.; Olson, E.N. Cardiac hypertrophy: the good, the bad, and the ugly. Annu. Rev. Physiol., 2003, 65, 45-79. (Pubitemid 38249147)
69. Wilkins, B.J.; Molkentin, J.D. Calcineurin and cardiac hypertrophy: where have we been? Where are we going? J. Physiol., 2002, 541, 1-8. (Pubitemid 35203232)
70. Balke, C.W.; Shorofsky, S.R. Alterations in calcium handling in cardiac hypertrophy and heart failure. Cardiovasc. Res., 1998, 37, 290-299 (Pubitemid 28165991)
71. Wilkins, B.J.; Molkentin, J.D. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem. Biophys. Res. Commun., 2004, 322, 1178-1191 (Pubitemid 39164648)
72. van Empel, V.P.; De Windt, L.J. Myocyte hypertrophy and apoptosis: a balancing act. Cardiovasc. Res., 2004, 63, 487-499
73. Ruwhof, C.; van der Laarse, A. Mechanical stress-induced cardiac hypertrophy: mechanisms and signal transduction pathways. Cardiovasc. Res., 2000, 47, 23-37. (Pubitemid 30408547)
74. Dorn, G.W., 2nd; Force, T. Protein kinase cascades in the regulation of cardiac hypertrophy. J. Clin. Invest., 2005, 115, 527-537 (Pubitemid 40322222)
75. Newton, A.C. Protein kinase C: structure, function, and regulation. J. Biol. Chem., 1995, 270, 28495-28498
76. Wang, J.; Liu, X.; Arneja, A.S.; Dhalla, N.S. Alterations in protein kinase A and protein kinase C levels in heart failure due to genetic cardiomyopathy. Can. J. Cardiol., 1999, 15, 683-690
77. McKinsey, T.A. Derepression of pathological cardiac genes by members of the CaM kinase superfamily. Cardiovasc. Res., 2007, 73, 667-677
78. Malhotra, A.; Kang, B.P.; Opawumi, D.; Belizaire, W.; Meggs, L.G. Molecular biology of protein kinase C signaling in cardiac myocytes. Mol. Cell Biochem., 2001, 225, 97-107. (Pubitemid 33014638)
79. Poole, A.W.; Pula, G.; Hers, I.; Crosby, D.; Jones, M.L. PKC-interacting proteins: from function to pharmacology. Trends Pharmacol. Sci., 2004, 25, 528-535
80. Molkentin, J.D.; Lu, J.R.; Antos, C.L.; Markham, B.; Richardson, J.; Robbins, J.; Grant, S.R.; Olson, E.N. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell, 1998, 93, 215-228 (Pubitemid 28180855)
81. Taigen, T.; De Windt, L.J.; Lim, H.W.; Molkentin, J.D. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc. Natl. Acad. Sci. U.S.A., 2000, 97, 1196-1201
82. Wilkins, B.J.; De Windt, L.J.; Bueno, O.F.; Braz, J.C.; Glascock, B.J.; Kimball, T.F.; Molkentin, J.D. Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth. Mol. Cell Biol., 2002, 22, 7603-7613
83. Wakasaki, H.; Koya, D.; Schoen, F.J.; Jirousek, M.R.; Ways, D.K.; Hoit, B.D.; Walsh, R.A.; King, G.L. Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc. Natl. Acad. Sci. U.S.A., 1997, 94, 9320-9325
84. Bowman, J.C.; Steinberg, S.F.; Jiang, T.; Geenen, D.L.; Fishman, G.I.; Buttrick, P.M. Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. J. Clin. Invest., 1997, 100, 2189-2195
85. Roman, B.B.; Geenen, D.L.; Leitges, M.; Buttrick, P.M. PKC-beta is not necessary for cardiac hypertrophy. Am. J. Physiol. Heart Circ. Physiol., 2001, 280, H2264-70.
86. Sentex, E.; Wang, X.; Liu, X.; Lukas, A.; Dhalla, N.S. Expression of protein kinase C isoforms in cardiac hypertrophy and heart failure due to volume overload. Can. J. Physiol. Pharmacol., 2006, 84, 227-238
87. Sucharov, C.C.; Mariner, P.D.; Nunley, K.R.; Long, C.; Leinwand, L.; Bristow, M.R. A beta1-adrenergic receptor CaM kinase II-dependent pathway mediates cardiac myocyte fetal gene induction. Am. J. Physiol. Heart Circ. Physiol., 2006, 291, H1299-308.
88. Zhang, R.; Khoo, M.S.; Wu, Y.; Yang, Y.; Grueter, C.E.; Ni, G.; Price, E.E., Jr.; Thiel, W.; Guatimosim, S.; Song, L.S.; Madu, E.C.; Shah, A.N.; Vishnivetskaya, T.A.; Atkinson, J.B.; Gurevich, V.V.; Salama, G.; Lederer, W.J.; Colbran, R.J.; Anderson, M.E. Calmodulin kinase II inhibition protects against structural heart disease. Nat. Med., 2005, 11, 409-417
89. Colomer, J.M.; Means, A.R. Chronic elevation of calmodulin in the ventricles of transgenic mice increases the autonomous activity of calmodulin-dependent protein kinase II, which regulates atrial natriuretic factor gene expression. Mol. Endocrinol., 2000, 14, 1125-1136
90. Iwata, M.; Maturana, A.; Hoshijima, M.; Tatematsu, K.; Okajima, T.; Vandenheede, J.R.; Van Lint, J.; Tanizawa, K.; Kuroda, S. PKCepsilon-PKD1 signaling complex at Z-discs plays a pivotal role in the cardiac hypertrophy induced by G-protein coupling receptor agonists. Biochem. Biophys. Res. Commun., 2005, 327, 1105-1113 (Pubitemid 40137983)
91. Harrison, B.C.; Kim, M.S.; van Rooij, E.; Plato, C.F.; Papst, P.J.; Vega, R.B.; McAnally, J.A.; Richardson, J.A.; Bassel-Duby, R.; Olson, E.N.; McKinsey, T.A. Regulation of cardiac stress signaling by protein kinase d1. Mol. Cell Biol., 2006, 26, 3875-3888 (Pubitemid 43726404)
92. Yamazaki, T.; Tobe, K.; Hoh, E.; Maemura, K.; Kaida, T.; Komuro, I.; Tamemoto, H.; Kadowaki, T.; Nagai, R.; Yazaki, Y. Mechanical loading activates mitogen-activated protein kinase and S6 peptide kinase in cultured rat cardiac myocytes. J. Biol. Chem., 1993, 268, 12069-12076 (Pubitemid 23168172)
93. Bueno, O.F.; De Windt, L.J.; Tymitz, K.M.; Witt, S.A.; Kimball, T.R.; Klevitsky, R.; Hewett, T.E.; Jones, S.P.; Lefer, D.J.; Peng, C.F.; Kitsis, R.N.; Molkentin, J.D. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J., 2000, 19, 6341-6350
94. Nicol, R.L.; Frey, N.; Pearson, G.; Cobb, M.; Richardson, J.; Olson, E.N. Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J., 2001, 20, 2757-2767
95. Wang, Y.; Huang, S.; Sah, V.P.; Ross, J., Jr.; Brown, J.H.; Han, J.; Chien, K.R. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J. Biol. Chem., 1998, 273, 2161-2168
96. Zhang, D.; Gaussin, V.; Taffet, G.E.; Belaguli, N.S.; Yamada, M.; Schwartz, R.J.; Michael, L.H.; Overbeek, P.A.; Schneider, M.D. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat. Med., 2000, 6, 556-563
97. Bodi, I.; Muth, J.N.; Hahn, H.S.; Petrashevskaya, N.N.; Rubio, M.; Koch, S.E.; Varadi, G.; Schwartz, A. Electrical remodeling in hearts from a calcium-dependent mouse model of hypertrophy and failure: complex nature of K+ current changes and action potential duration. J. Am. Coll. Cardiol., 2003, 41, 1611-1622 (Pubitemid 36543383)
98. Muth, J.N.; Bodi, I.; Lewis, W.; Varadi, G.; Schwartz, A. A Ca(2+)-dependent transgenic model of cardiac hypertrophy: A role for protein kinase Calpha. Circulation, 2001, 103, 140-147
99. Song, L.S.; Guia, A.; Muth, J.N.; Rubio, M.; Wang, S.Q.; Xiao, R.P.; Josephson, I.R.; Lakatta, E.G.; Schwartz, A.; Cheng, H. Ca(2+) signaling in cardiac myocytes overexpressing the alpha(1) subunit of L-type Ca(2+) channel. Circ. Res., 2002, 90, 174-181
100. Nakayama, H.; Chen, X.; Baines, C.P.; Klevitsky, R.; Zhang, X.; Zhang, H.; Jaleel, N.; Chua, B.H.; Hewett, T.E.; Robbins, J.; Houser, S.R.; Molkentin, J.D. Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J. Clin. Invest., 2007, 117, 2431-2444
101. Haase, H.; Kresse, A.; Hohaus, A.; Schulte, H.D.; Maier, M.; Osterziel, K.J.; Lange, P.E.; Morano, I. Expression of calcium channel subunits in the normal and diseased human myocardium. J. Mol. Med., 1996, 74, 99-104. (Pubitemid 26075632)
102. Hullin, R.; Khan, I.F.; Wirtz, S.; Mohacsi, P.; Varadi, G.; Schwartz, A.; Herzig, S. Cardiac L-type calcium channel beta-subunits expressed in human heart have differential effects on single channel characteristics. J. Biol. Chem., 2003, 278, 21623-21630 (Pubitemid 36792562)
103. Hullin, R.; Matthes, J.; von Vietinghoff, S.; Bodi, I.; Rubio, M.; D'Souza, K.; Friedrich Khan, I.; Rottlander, D.; Hoppe, U.C.; Mohacsi, P.; Schmitteckert, E.; Gilsbach, R.; Bunemann, M.; Hein, L.; Schwartz, A.; Herzig, S. Increased expression of the auxiliary beta2-subunit of ventricular L-type Ca2+ channels leads to single-channel activity characteristic of heart failure. PLoS ONE, 2007, 2, e292.
104. Splawski, I.; Timothy, K.W.; Decher, N.; Kumar, P.; Sachse, F.B.; Beggs, A.H.; Sanguinetti, M.C.; Keating, M.T. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc. Natl. Acad. Sci. U.S.A., 2005, 102, 8089-96; discussion 86-88
105. Bolli, R. Causative role of oxyradicals in myocardial stunning: a proven hypothesis. A brief review of the evidence demonstrating a major role of reactive oxygen species in several forms of postischemic dysfunction. Basic Res. Cardiol., 1998, 93, 156-162 (Pubitemid 28339970)
106. Grieve, D.J.; Byrne, J.A.; Cave, A.C.; Shah, A.M. Role of oxidative stress in cardiac remodelling after myocardial infarction. Heart Lung Circ., 2004, 13, 132-138 (Pubitemid 38877983)
107. Hool, L.C. Reactive oxygen species in cardiac signalling: from mitochondria to plasma membrane ion channels. Clin. Exp. Pharmacol. Physiol., 2006, 33, 146-151
108. Antunes, F.; Cadenas, E. Estimation of H2O2 gradients across biomembranes. FEBS Lett., 2000, 475, 121-126
109. Stone, J.R.; Yang, S. Hydrogen peroxide: a signaling messenger. Antioxid Redox Signal., 2006, 8, 243-270
110. Makino, N.; Sasaki, K.; Hashida, K.; Sakakura, Y. A metabolic model describing the H2O2 elimination by mammalian cells including H2O2 permeation through cytoplasmic and peroxisomal membranes: comparison with experimental data. Biochim. Biophys. Acta, 2004, 1673, 149-159
111. Seaver, L.C.; Imlay, J.A. Hydrogen peroxide fluxes and compartmentalization inside growing Escherichia coli. J. Bacteriol., 2001, 183, 7182-7189
112. Pizzetti, G.; Mailhac, A.; Li Volsi, L.; Di Marco, F.; Lu, C.; Margonato, A.; Chierchia, S.L. Beneficial effects of diltiazem during myocardial reperfusion: a randomized trial in acute myocardial infarction. Ital. Heart J., 2001, 2, 757-765 (Pubitemid 33115110)
113. Bestehorn, H.P.; Neumann, F.J.; Buttner, H.J.; Betz, P.; Sturzenhofecker, P.; von Hodenberg, E.; Verdun, A.; Levai, L.; Monassier, J.P.; Roskamm, H. Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention: the randomized, double-blind, placebo-controlled, multicenter Verapamil Slow-Release for Prevention of Cardiovascular Events After Angioplasty (VESPA) Trial. J. Am. Coll. Cardiol., 2004, 43, 2160-2165
114. Umemoto, S.; Tanaka, M.; Kawahara, S.; Kubo, M.; Umeji, K.; Hashimoto, R.; Matsuzaki, M. Calcium antagonist reduces oxidative stress by upregulating Cu/Zn superoxide dismutase in stroke-prone spontaneously hypertensive rats. Hypertens Res., 2004, 27, 877-885 (Pubitemid 40309454)
115. Wang, Q.D.; Pernow, J.; Sjoquist, P.O.; Ryden, L. Pharmacological possibilities for protection against myocardial reperfusion injury. Cardiovasc. Res., 2002, 55, 25-37. (Pubitemid 34618530)
116. Kloner, R.A.; Jennings, R.B. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 2. Circulation, 2001, 104, 3158-3167 (Pubitemid 34014074)
117. Romero, M.; Sanchez, I.; Pujol, M.D. New advances in the field of calcium channel antagonists: cardiovascular effects and structure-activity relationships. Curr. Med. Chem. Cardiovasc. Hematol. Agents, 2003, 1, 113-141
118. Hockerman, G.H.; Peterson, B.Z.; Johnson, B.D.; Catterall, W.A. Molecular determinants of drug binding and action on L-type calcium channels. Annu. Rev. Pharmacol. Toxicol., 1997, 37, 361-396
119. Roux, S.; Buhler, M.; Clozel, J.P. Mechanism of the antiischemic effect of mibefradil, a selective T calcium channel blocker in dogs: comparison with amlodipine. J. Cardiovasc. Pharmacol., 1996, 27, 132-139
120. Clozel, J.P.; Banken, L.; Osterrieder, W. Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil. J. Cardiovasc. Pharmacol., 1989, 14, 713-721
121. Triggle, D.J. Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefradil, a new calcium antagonist. Am. J. Cardiol., 1996, 78, 7-12.
122. Mishra, S.K.; Hermsmeyer, K. Selective inhibition of T-type Ca2+ channels by Ro 40-5967. Circ. Res., 1994, 75, 144-148 (Pubitemid 24187745)
123. Schmitt, R.; Clozel, J.P.; Iberg, N.; Buhler, F.R. Mibefradil prevents neointima formation after vascular injury in rats. Possible role of the blockade of the T-type voltage-operated calcium channel. Arterioscler. Thromb. Vasc. Biol., 1995, 15, 1161-1165
124. Triggle, D.J. Voltage-gated ion channels as drug targets. Methods and principles in medicinal chemistry; v. 29., 2006, 29, xii, 479 p.
125. Iqbal, N.; Akula, M.R.; Vo, D.; Matowe, W.C.; McEwen, C.A.; Wolowyk, M.W.; Knaus, E.E. Synthesis, rotamer orientation, and calcium channel modulation activities of alkyl and 2-phenethyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(3- or 6-substituted-2-pyridyl)-5-pyridinecarboxylates. J. Med. Chem., 1998, 41, 1827-1837
126. Triggle, D.J. 1,4-Dihydropyridine calcium channel ligands: Selectivity of action. The roles of pharmacokinetics, state-dependent interactions, channel isoforms, and other factors. Drug Dev. Res., 2003, 58, 5-17.
127. Zou, Y.; Yamazaki, T.; Nakagawa, K.; Yamada, H.; Iriguchi, N.; Toko, H.; Takano, H.; Akazawa, H.; Nagai, R.; Komuro, I. Continuous blockade of L-type Ca2+ channels suppresses activation of calcineurin and development of cardiac hypertrophy in spontaneously hypertensive rats. Hypertens Res., 2002, 25, 117-124 (Pubitemid 34196304)
128. Tomassoni, D.; Sabbatini, M.; Amenta, F. Effect of different dihydropyridine-type Ca2+ antagonists on left ventricle hypertrophy and coronary changes in spontaneously hypertensive rats. J. Cardiovasc. Pharmacol., 2003, 41, 544-552 (Pubitemid 36373791)
129. Wang, D.S.; Xie, H.H.; Shen, F.M.; Cai, G.J.; Su, D.F. Blood pressure variability, cardiac baroreflex sensitivity and organ damage in experimentally hypertensive rats. Clin. Exp. Pharmacol. Physiol., 2005, 32, 545-552 (Pubitemid 41021068)
130. Zobel, C.; Rana, O.R.; Saygili, E.; Bolck, B.; Saygili, E.; Diedrichs, H.; Reuter, H.; Frank, K.; Muller-Ehmsen, J.; Pfitzer, G.; Schwinger, R.H. Mechanisms of Ca2+-dependent calcineurin activation in mechanical stretch-induced hypertrophy. Cardiology, 2007, 107, 281-290
131. Held, P.H.; Yusuf, S.; Furberg, C.D. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ, 1989, 299, 1187-1192 (Pubitemid 19281166)
132. Sirnes, P.A.; Overskeid, K.; Pedersen, T.R.; Bathen, J.; Drivenes, A.; Froland, G.S.; Kjekshus, J.K.; Landmark, K.; Rokseth, R.; Sirnes, K.E.; et al. Evolution of infarct size during the early use of nifedipine in patients with acute myocardial infarction: the Norwegian Nifedipine Multicenter Trial. Circulation, 1984, 70, 638-644 (Pubitemid 14020662)
133. Elkayam, U.; Amin, J.; Mehra, A.; Vasquez, J.; Weber, L.; Rahimtoola, S.H. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation, 1990, 82, 1954-1961
134. Bellocci, F.; Ansalone, G.; Santarelli, P.; Loperfido, F.; Scabbia, E.; Zecchi, P.; Manzoli, U. Oral nifedipine in the long-term management of severe chronic heart failure. J. Cardiovasc. Pharmacol., 1982, 4, 847-855
135. Klugmann, S.; Salvi, A.; Camerini, F. Haemodynamic effects of nifedipine in heart failure. Br. Heart J., 1980, 43, 440-446 (Pubitemid 10083031)
136. Matsumoto, S.; Ito, T.; Sada, T.; Takahashi, M.; Su, K.M.; Ueda, A.; Okabe, F.; Sato, M.; Sekine, I.; Ito, Y. Hemodynamic effects of nifedipine in congestive heart failure. Am. J. Cardiol., 1980, 46, 476-480 (Pubitemid 10059399)
137. Cantelli, I.; Pavesi, P.C.; Parchi, C.; Naccarella, F.; Bracchetti, D. Acute hemodynamic effects of combined therapy with digoxin and nifedipine in patients with chronic heart failure. Am. Heart J., 1983, 106, 308-315
138. Magorien, R.D.; Leier, C.V.; Kolibash, A.J.; Barbush, T.J.; Unverferth, D.V. Beneficial effects of nifedipine on rest and exercise myocardial energetics in patients with congestive heart failure. Circulation, 1984, 70, 884-890 (Pubitemid 15205454)
139. Miller, A.B.; Conetta, D.A.; Bass, T.A. Sublingual nifedipine: acute effects in severe chronic congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am. J. Cardiol., 1985, 55, 1359-1362 (Pubitemid 15035202)
140. Baughman, K.L. Calcium channel blocking agents in congestive heart failure. Am. J. Med., 1986, 80, 46-50. (Pubitemid 16012622)
141. Green, J.A.; Nara, A.R.; Gengo, F.M. Characterization of the dose-concentration-dependent hemodynamic effects of nifedipine in heart failure. J. Clin. Pharmacol., 1987, 27, 574-581 (Pubitemid 17133100)
142. Elkayam, U.; Weber, L.; McKay, C.; Rahimtoola, S. Spectrum of acute hemodynamic effects of nifedipine in severe congestive heart failure. Am. J. Cardiol., 1985, 56, 560-566 (Pubitemid 15236666)
143. Packer, M.; Kessler, P.D.; Lee, W.H. Calcium-channel blockade in the management of severe chronic congestive heart failure: a bridge too far. Circulation, 1987, 75, V56-64.
144. Cohn, J.N. Current therapy of the failing heart. Circulation, 1988, 78, 1099-1107
145. Furberg, C.D.; Psaty, B.M.; Meyer, J.V. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation, 1995, 92, 1326-1331
146. Croom, K.F.; Wellington, K. Modified-release nifedipine: a review of the use of modified-release formulations in the treatment of hypertension and angina pectoris. Drugs, 2006, 66, 497-528.
147. Murdoch, D.; Brogden, R.N. Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders. Drugs, 1991, 41, 737-779
148. Brogden, R.N.; McTavish, D. Nifedipine gastrointestinal therapeutic system (GITS). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris. Drugs, 1995, 50, 495-512.
149. Gross, G.J.; Farber, N.E.; Pieper, G.M. Effects of amlodipine on myocardial ischemia-reperfusion injury in dogs. Am. J. Cardiol., 1989, 64, 94I-100I.
150. Burges, R.A.; Dodd, M.G.; Gardiner, D.G. Pharmacologic profile of amlodipine. Am J Cardiol, 1989, 64, 10I-18I; discussion 18I-20I.
151. Nayler, W.G. The effect of amlodipine on hypertension-induced cardiac hypertrophy and reperfusion-induced calcium overload. J. Cardiovasc. Pharmacol., 1988, 12(Suppl 7), S42-4.
152. Burges, R.A.; Carter, A.J.; Gardiner, D.G.; Higgins, A.J. Amlodipine, a new dihydropyridine calcium channel blocker with slow onset and long duration of
153. Stopher, D.A.; Beresford, A.P.; Macrae, P.V.; Humphrey, M.J. The metabolism and pharmacokinetics of amlodipine in humans and animals. J. Cardiovasc. Pharmacol., 1988, 12(Suppl 7), S55-9.
154. Nayler, W.G. Amlodipine pretreatment and the ischemic heart. Am. J. Cardiol., 1989, 64, 65I-69I; discussion 69I-70I.
155. Hoff, P.T.; Tamura, Y.; Lucchesi, B.R. Cardioprotective effects of amlodipine in the ischemic-reperfused heart. Am. J. Cardiol., 1989, 64, 101I-15I discussion 15I-16I.
156. Deanfield, J.E.; Detry, J.M.; Lichtlen, P.R.; Magnani, B.; Sellier, P.; Thaulow, E. Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: double-blind Circadian Anti-Ischemia Program in Europe (CAPE Trial). J. Am. Coll. Cardiol., 1994, 24, 1460-1467 (Pubitemid 24344240)
157. Budriesi, R.; Cosimelli, B.; Ioan, P.; Carosati, E.; Ugenti, M.P.; Spisani, R. Diltiazem analogues: the last ten years on structure activity relationships. Curr. Med. Chem., 2007, 14, 279-287 (Pubitemid 46299698)
158. Buckley, M.M.; Grant, S.M.; Goa, K.L.; McTavish, D.; Sorkin, E.M. Diltiazem. A reappraisal of its pharmacological properties and therapeutic use. Drugs, 1990, 39, 757-806. (Pubitemid 20176249)
159. Bush, L.R.; Romson, J.L.; Ash, J.L.; Lucchesi, B.R. Effect of diltiazem on extent of ultimate myocardial injury resulting from temporary coronary artery occlusion in dogs. J. Cardiovasc. Pharmacol., 1982, 4, 285-296
160. Semsarian, C.; Ahmad, I.; Giewat, M.; Georgakopoulos, D.; Schmitt, J.P.; McConnell, B.K.; Reiken, S.; Mende, U.; Marks, A.R.; Kass, D.A.; Seidman, C.E.; Seidman, J.G. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J. Clin. Invest., 2002, 109, 1013-1020
161. Westermann, D.; Knollmann, B.C.; Steendijk, P.; Rutschow, S.; Riad, A.; Pauschinger, M.; Potter, J.D.; Schultheiss, H.P.; Tschope, C. Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy. Eur. J. Heart Fail, 2006, 8, 115-121 (Pubitemid 43240843)
162. Gibson, R.S.; Boden, W.E.; Theroux, P.; Strauss, H.D.; Pratt, C.M.; Gheorghiade, M.; Capone, R.J.; Crawford, M.H.; Schlant, R.C.; Kleiger, R.E.; et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. N. Engl. J. Med., 1986, 315, 423-429
163. Zannad, F.; Amor, M.; Karcher, G.; Maurin, P.; Ethevenot, G.; Sebag, C.; Bertrand, A.; Pernot, C.; Gilgenkrantz, J.M. Effect of diltiazem on myocardial infarct size estimated by enzyme release, serial thallium-201 single-photon emission computed tomography and radionuclide angiography. Am. J. Cardiol., 1988, 61, 1172-1177
164. Campiani, G.; Fiorini, I.; De Filippis, M.P.; Ciani, S.M.; Garofalo, A.; Nacci, V.; Giorgi, G.; Sega, A.; Botta, M.; Chiarini, A.; Budriesi, R.; Bruni, G.; Romeo, M.R.; Manzoni, C.; Mennini, T. Cardiovascular characterization of pyrrolo[2,1-d][1,5]benzothiazepine derivatives binding selectively to the peripheral-type benzodiazepine receptor (PBR): from dual PBR affinity and calcium antagonist activity to novel and selective calcium entry blockers. J. Med. Chem., 1996, 39, 2922-2938
165. Yamamoto, K.; Fujita, M.; Tabashi, K.; Kawashima, Y.; Kato, E.; Oya, M.; Iso, T.; Iwao, J. Novel calcium antagonists. Synthesis and structure-activity relationship studies of benzothiazoline derivatives. J. Med. Chem., 1988, 31, 919-930
166. Kimball, S.D.; Floyd, D.M.; Das, J.; Hunt, J.T.; Krapcho, J.; Rovnyak, G.; Duff, K.J.; Lee, V.G.; Moquin, R.V.; Turk, C.F.; et al. Benzazepinone calcium channel blockers. 4. Structure-activity overview and intracellular binding site. J. Med. Chem., 1992, 35, 780-793
167. Campiani, G.; Garofalo, A.; Fiorini, I.; Botta, M.; Nacci, V.; Tafi, A.; Chiarini, A.; Budriesi, R.; Bruni, G.; Romeo, M.R. Pyrrolo[2,1-c][1,4] benzothiazines: synthesis, structure-activity relationships, molecular modeling studies, and cardiovascular activity. J. Med. Chem., 1995, 38, 4393-4410
168. Lee, K.S.; Tsien, R.W. Mechanism of calcium channel blockade by verapamil, D600, diltiazem and nitrendipine in single dialysed heart cells. Nature, 1983, 302, 790-794
169. Sanguinetti, M.C.; Kass, R.S. Voltage-dependent block of calcium channel current in the calf cardiac Purkinje fiber by dihydropyridine calcium channel antagonists. Circ. Res., 1984, 55, 336-348 (Pubitemid 14047495)
170. Uehara, A.; Hume, J.R. Interactions of organic calcium channel antagonists with calcium channels in single frog atrial cells. J. Gen. Physiol., 1985, 85, 621-647
171. Kloner, R.A.; Braunwald, E. Effects of calcium antagonists on infarcting myocardium. Am. J. Cardiol., 1987, 59, 84B-94B. (Pubitemid 17026217)
172. Prisant, L.M. Verapamil revisited: a transition in novel drug delivery systems and outcomes. Heart Dis., 2001, 3, 55-62.
173. Smith, H.J.; Singh, B.N.; Nisbet, H.D.; Norris, R.M. Effects of verapamil on infarct size following experimental coronary occlusion. Cardiovasc. Res., 1975, 9, 569-578
174. Wende, W.; Bleifeld, W.; Meyer, J.; Stuhlen, H.W. Reduction of the size of acute, experimental myocardial infarction by Verapamil. Basic Res. Cardiol., 1975, 70, 198-208.
175. Reimer, K.A.; Lowe, J.E.; Jennings, R.B. Effect of the calcium antagonist verapamil on necrosis following temporary coronary artery occlusion in dogs. Circulation, 1977, 55, 581-587
176. Smith, H.J.; Singh, B.N.; Norris, R.M.; Nisbet, H.D.; John, M.B.; Hurley, P.J. The effect of verapamil on experimental myocardial ischaemia with a particular reference to regional myocardial blood flow and metabolism. Aust. N. Z. J. Med., 1977, 7, 114-121 (Pubitemid 8123216)
177. Lefer, A.M.; Polansky, E.W.; Bianchi, C.P.; Narayan, S. Influence of verapamil on cellular integrity and electrolyte concentrations of ischemic myocardial tissue in the cat. Basic Res. Cardiol., 1979, 74, 555-567 (Pubitemid 10201292)
178. da Luz, P.L.; Monteiro de Barros, L.F.; Leite, J.J.; Pileggi, F.; Decourt, L.V. Effect of verapamil on regional coronary and myocardial perfusion during acute coronary occlusion. Am. J. Cardiol., 1980, 45, 269-275 (Pubitemid 10187403)
179. Anand, I.S.; Sharma, P.L.; Chakravarti, R.N.; Wahi, P.L. Experimental myocardial infarction in rhesus monkeys. Verapamil pretreatment in the reduction of infarct size. Adv. Myocardio.l, 1980, 2, 425-433
180. DeBoer, L.W.; Strauss, H.W.; Kloner, R.A.; Rude, R.E.; Davis, R.F.; Maroko, P.R.; Braunwald, E. Autoradiographic method for measuring the ischemic myocardium at risk: effects of verapamil on infarct size aftr experimental coronary artery occlusion. Proc. Natl. Acad. Sci. U.S.A., 1980, 77, 6119-6123
181. Yellon, D.M.; Hearse, D.J.; Maxwell, M.P.; Chambers, D.E.; Downey, J.M. Sustained limitation of myocardial necrosis 24 hours after coronary artery occlusion: verapamil infusion in dogs with small myocardial infarcts. Am. J. Cardiol., 1983, 51, 1409-1413
182. Reimer, K.A.; Jennings, R.B. Verapamil in two reperfusion models of myocardial infarction. Temporary protection of severely ischemic myocardium without limitation of ultimate infarct size. Lab. Invest., 1984, 51, 655-666
183. Reimer, K.A.; Jennings, R.B.; Cobb, F.R.; Murdock, R.H.; Greenfield, J.C., Jr.; Becker, L.C.; Bulkley, B.H.; Hutchins, G.M.; Schwartz, R.P., Jr.; Bailey, K.R.; et al. Animal models for protecting ischemic myocardium: results of the NHLBI Cooperative Study. Comparison of unconscious and conscious dog models. Circ. Res., 1985, 56, 651-665
184. Lo, H.M.; Kloner, R.A.; Braunwald, E. Effect of intracoronary verapamil on infarct size in the ischemic, reperfused canine heart: critical importance of the timing of treatment. Am. J. Cardiol., 1985, 56, 672-677 (Pubitemid 16203696)
185. Karlsberg, R.P.; Henry, P.D.; Ahmed, S.A.; Sobel, B.E.; Roberts, R. Lack of protection of ischemic myocardium by verapamil in conscious dogs. Eur. J. Pharmacol., 1977, 42, 339-346
186. Alps, B.J.; Calder, C.; Wilson, A. The beneficial effect of nicardipine compared with nifedipine and verapamil in limiting myocardial infarct size in baboons. Arzneimittelforschung, 1983, 33, 868-876
187. Davenport, N.; Goldstein, R.E.; Bolli, R.; Epstein, S.E. Blood flow to infarct and surviving myocardium: implications regarding the action of verapamil on the acutely ischemic dog heart. J. Am. Coll. Cardiol., 1984, 3, 956-965
188. Thuesen, L.; Jorgensen, J.R.; Kvistgaard, H.J.; Sorensen, J.A.; Vaeth, M.; Jensen, E.B.; Jensen, J.J.; Hagerup, L. Effect of verapamil on enzyme release after early intravenous administration in acute myocardial infarction: double blind randomised trial. Br. Med. J. (Clin. Res. Ed.), 1983, 286, 1107-1108
189. Bussmann, W.D.; Seher, W.; Gruengras, M. Reduction of creatine kinase and creatine kinase-MB indexes of infarct size by intravenous verapamil. Am. J. Cardiol., 1984, 54, 1224-1230 (Pubitemid 15220543)
190. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II - DAVIT II). Am. J. Cardiol., 1990, 66, 779-785
191. Elkayam, U. Calcium channel blockers in heart failure. Cardiology, 1998, 89(Suppl 1), 38-46. (Pubitemid 28101875)
192. Abernethy, D.R. Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonist. Am. J. Cardiol., 1997, 80, 4C-11C.
193. Ezzaher, A.; el Houda Bouanani, N.; Su, J.B.; Hittinger, L.; Crozatier, B. Increased negative inotropic effect of calcium-channel blockers in hypertrophied and failing rabbit heart. J. Pharmacol. Exp. Ther., 1991, 257, 466-471
194. Su, J.; Renaud, N.; Carayon, A.; Crozatier, B.; Hittinger, L. Effects of the calcium channel blockers, diltiazem and Ro 40-5967, on systemic haemodynamics and plasma noradrenaline levels in conscious dogs with pacing-induced heart failure. Br. J. Pharmacol., 1994, 113, 395-402. (Pubitemid 24310734)
195. Guth, B.D. Reduction of exercise-induced regional contractile dysfunction in dogs using a novel calcium channel blocker (Ro 40-5967). Cardiovasc. Drugs Ther., 1992, 6, 167-171
196. Sandmann, S.; Spitznagel, H.; Chung, O.; Xia, Q.G.; Illner, S.; Janichen, G.; Rossius, B.; Daemen, M.J.; Unger, T. Effects of the calcium channel antagonist mibefradil on haemodynamic and morphological parameters in myocardial infarction-induced cardiac failure in rats. Cardiovasc. Res., 1998, 39, 339-350 (Pubitemid 28346530)
197. Rutledge, A.; Triggle, D.J. The binding interactions of Ro 40-5967 at the L-type Ca2+ channel in cardiac tissue. Eur. J. Pharmacol., 1995, 280, 155-158
198. Veniant, M.; Clozel, J.P.; Hess, P.; Wolfgang, R. Hemodynamic profile of Ro 40-5967 in conscious rats: comparison with diltiazem, verapamil, and amlodipine. J. Cardiovasc. Pharmacol., 1991, 18(Suppl 10), S55-8.
199. Orito, K.; Satoh, K.; Taira, N. Cardiovascular profile of Ro 40-5967, a new nondihydropyridine calcium antagonist, delineated in isolated, blood-perfused dog hearts. J. Cardiovasc. Pharmacol., 1993, 22, 293-299 (Pubitemid 23225158)
200. Mulder, P.; Richard, V.; Compagnon, P.; Henry, J.P.; Lallemand, F.; Clozel, J.P.; Koen, R.; Mace, B.; Thuillez, C. Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure. J. Am. Coll. Cardiol., 1997, 29, 416-421 (Pubitemid 27059975)
201. Muntinga, H.J.; van der Vring, J.A.; Niemeyer, M.G.; van den Berg, F.; Knol, H.R.; Bernink, P.J.; van der Wall, E.E.; Blanksma, P.K.; Lie, K.I. Effect of mibefradil on left ventricular diastolic function in patients with congestive heart failure. J. Cardiovasc. Pharmacol., 1996, 27, 652-656 (Pubitemid 26134241)
202. Bernink, P.J.; Prager, G.; Schelling, A.; Kobrin, I. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Mibefradil International Study Group. Hypertension, 1996, 27, 426-432 (Pubitemid 26083057)
203. Bursztyn, M.; Kadr, H.; Tilvis, R.; Martina, B.; Oigman, W.; Talberg, J.; Kobrin, I. Mibefradil, a novel calcium antagonist, in elderly patients with hypertension: favorable hemodynamics and pharmacokinetics. Am. Heart J., 1997, 134, 238-247
204. Gillum, R.F.; Makuc, D.M.; Feldman, J.J. Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study. Am. Heart J., 1991, 121, 172-177
205. Thaulow, E.; Erikssen, J.E. How important is heart rate? J. Hypertens Suppl., 1991, 9, S27-30.
206. Dyer, A.R.; Persky, V.; Stamler, J.; Paul, O.; Shekelle, R.B.; Berkson, D.M.; Lepper, M.; Schoenberger, J.A.; Lindberg, H.A. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am. J. Epidemiol., 1980, 112, 736-749
207. Perski, A.; Olsson, G.; Landou, C.; de Faire, U.; Theorell, T.; Hamsten, A. Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am. Heart J., 1992, 123, 609-616
208. Kannel, W.B.; Kannel, C.; Paffenbarger, R.S., Jr.; Cupples, L.A. Heart rate and cardiovascular mortality: the Framingham Study. Am. Heart J., 1987, 113, 1489-1494 (Pubitemid 17092823)
209. Angus, J.A.; Wright, C.E.; Xi, Q. Targetting voltage-gated calcium channels in cardiovascular therapy. Lancet, 2000, 356, 1287-1289 (Pubitemid 30831846)
210. Sanguinetti, M.C.; Bennett, P.B. Antiarrhythmic drug target choices and screening. Circ. Res., 2003, 93, 491-499
211. Levine, T.B.; Bernink, P.J.; Caspi, A.; Elkayam, U.; Geltman, E.M.; Greenberg, B.; McKenna, W.J.; Ghali, J.K.; Giles, T.D.; Marmor, A.; Reisin, L.H.; Ammon, S.; Lindberg, E. Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study. Mortality Assessment in Congestive Heart Failure Trial. Circulation, 2000, 101, 758-764
212. Brogden, R.N.; Markham, A. Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris. Drugs, 1997, 54, 774-793 (Pubitemid 27480246)
213. Fabre, G.; Julian, B.; Saint-Aubert, B.; Joyeux, H.; Berger, Y. Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab. Dispos., 1993, 21, 978-985 (Pubitemid 23348332)
214. Mullins, M.E.; Horowitz, B.Z.; Linden, D.H.; Smith, G.W.; Norton, R.L.; Stump, J. Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers. JAMA, 1998, 280, 157-158 (Pubitemid 28498388)
215. Siepmann, M.; Kleinbloesem, C.; Kirch, W. The interaction of the calcium antagonist RO 40-5967 with digoxin. Br. J. Clin. Pharmacol., 1995, 39, 491-496
216. Varis, T.; Backman, J.T.; Kivisto, K.T.; Neuvonen, P.J. Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone. Clin. Pharmacol. Ther., 2000, 67, 215-221
217. Welker, H.A.; Wiltshire, H.; Bullingham, R. Clinical pharmacokinetics of mibefradil. Clin. Pharmacokinet., 1998, 35, 405-423
218. Spoendlin, M.; Peters, J.; Welker, H.; Bock, A.; Thiel, G. Pharmacokinetic interaction between oral cyclosporin and mibefradil in stabilized post-renal-transplant patients. Nephrol. Dial Transplant, 1998, 13, 1787-1791 (Pubitemid 28306812)
219. Schmassmann-Suhijar, D.; Bullingham, R.; Gasser, R.; Schmutz, J.; Haefeli, W.E. Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet, 1998, 351, 1929-1930
220. Krahenbuhl, S.; Menafoglio, A.; Giostra, E.; Gallino, A. Serious interaction between mibefradil and tacrolimus. Transplantation, 1998, 66, 1113-1115
221. Zhou, S.F. Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4. Curr. Pharm. Des., 2008, 14, 990-1000.
222. Welling, A.; Ludwig, A.; Zimmer, S.; Klugbauer, N.; Flockerzi, V.; Hofmann, F. Alternatively spliced IS6 segments of the alpha 1C gene determine the tissue-specific dihydropyridine sensitivity of cardiac and vascular smooth muscle L-type Ca2+ channels. Circ. Res., 1997, 81, 526-532 (Pubitemid 27432739)
223. Mikami, A.; Imoto, K.; Tanabe, T.; Niidome, T.; Mori, Y.; Takeshima, H.; Narumiya, S.; Numa, S. Primary structure and functional expression of the cardiac dihydropyridine-sensitive calcium channel. Nature, 1989, 340, 230-233 (Pubitemid 19171586)
224. Biel, M.; Ruth, P.; Bosse, E.; Hullin, R.; Stuhmer, W.; Flockerzi, V.; Hofmann, F. Primary structure and functional expression of a high voltage activated calcium channel from rabbit lung. FEBS Lett., 1990, 269, 409-412 (Pubitemid 20273837)
225. Liao, P.; Yong, T.F.; Liang, M.C.; Yue, D.T.; Soong, T.W. Splicing for alternative structures of Cav1.2 Ca2+ channels in cardiac and smooth muscles. Cardiovasc. Res., 2005, 68, 197-203.
226. Yadav, A.; Awasthi, A.; Rao, N.K. Mechanistic aspects of benzothiazepines: a class of antiarrhythmic drugs. Eur. J. Med. Chem., 2009, 44, 1-6.
227. Bean, B.P. Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state. Proc. Natl. Acad. Sci. U.S.A., 1984, 81, 6388-6392
228. Triggle, D.J. Calcium-channel drugs: structure-function relationships and selectivity of action. J. Cardiovasc. Pharmacol., 1991, 18(Suppl 10), S1-6.
229. Seisenberger, C.; Specht, V.; Welling, A.; Platzer, J.; Pfeifer, A.; Kuhbandner, S.; Striessnig, J.; Klugbauer, N.; Feil, R.; Hofmann, F. Functional embryonic cardiomyocytes after disruption of the L-type alpha1C (Cav1.2) calcium channel gene in the mouse. J. Biol. Chem., 2000, 275, 39193-39199 (Pubitemid 32058936)
230. Antos, C.L.; Frey, N.; Marx, S.O.; Reiken, S.; Gaburjakova, M.; Richardson, J.A.; Marks, A.R.; Olson, E.N. Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase a. Circ. Res., 2001, 89, 997-1004.
231. El-Armouche, A.; Wittkopper, K.; Degenhardt, F.; Weinberger, F.; Didie, M.; Melnychenko, I.; Grimm, M.; Peeck, M.; Zimmermann, W.H.; Unsold, B.; Hasenfuss, G.; Dobrev, D.; Eschenhagen, T. Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy. Cardiovasc. Res., 2008, 24, 24.
232. Beguin, P.; Nagashima, K.; Gonoi, T.; Shibasaki, T.; Takahashi, K.; Kashima, Y.; Ozaki, N.; Geering, K.; Iwanaga, T.; Seino, S. Regulation of Ca2+ channel expression at the cell surface by the small G-protein kir/Gem. Nature, 2001, 411, 701-706 (Pubitemid 32531676)
233. Finlin, B.S.; Crump, S.M.; Satin, J.; Andres, D.A. Regulation of voltage-gated calcium channel activity by the Rem and Rad GTPases. Proc. Natl. Acad. Sci. U.S.A., 2003, 100, 14469-14474 (Pubitemid 37499260)
234. Murata, M.; Cingolani, E.; McDonald, A.D.; Donahue, J.K.; Marban, E. Creation of a genetic calcium channel blocker by targeted gem gene transfer in the heart. Circ. Res., 2004, 95, 398-405. Epub 2004 Jul 8. (Pubitemid 39100458)
235. Telemaque, S.; Sonkusare, S.; Grain, T.; Rhee, S.W.; Stimers, J.R.; Rusch, N.J.; Marsh, J.D. Design of mutant beta2 subunits as decoy molecules to reduce the expression of functional Ca2+ channels in cardiac cells. J. Pharmacol. Exp. Ther., 2008, 325, 37-46. Epub 2008 Jan 9.
236. Fearon, I.M.; Varadi, G.; Koch, S.; Isaacsohn, I.; Ball, S.G.; Peers, C. Splice variants reveal the region involved in oxygen sensing by recombinant human L-type Ca(2+) channels. Circ. Res., 2000, 87, 537-539 (Pubitemid 30745346)
237. Abernethy, D.R.; Schwartz, J.B. Calcium-antagonist drugs. N. Engl. J. Med., 1999, 341, 1447-1457